---
title: "Cellyan Biotechnology Stock Sinks 21% After Hours: Here's What Happened"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292992523.md"
description: "Cellyan Biotechnology (NASDAQ: HKPD) shares plunged over 20% in after-hours trading following news that Nasdaq granted an additional 180-day compliance period to meet the $1.00 minimum bid price requirement, with a deadline of January 11, 2027. The stock closed regular trading down 5.18% at $0.43. While Nasdaq noted the company meets other listing standards, Cellyan cautioned there is no assurance it will regain compliance within the allotted time."
datetime: "2026-07-17T05:36:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292992523.md)
  - [en](https://longbridge.com/en/news/292992523.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292992523.md)
generator: "portal-rs"
---

# Cellyan Biotechnology Stock Sinks 21% After Hours: Here's What Happened

**Cellyan Biotechnology Co. Ltd** (NASDAQ:HKPD) shares remained under pressure after the company disclosed that it received an additional 180-day compliance period from Nasdaq to regain compliance with the exchange’s minimum $1.00 bid price requirement.

HKPD closed Thursday’s regular session down 5.18% at $0.43. The stock fell 20.79% to $0.34 in after-hours trading.

Cellyan Biotechnology provides over-the-counter pharmaceutical cross-border e-commerce supply chain and procurement services through its Hong Kong subsidiaries.

## Nasdaq Grants More Time To Regain Compliance

In a press release issued Thursday, the company said Nasdaq granted it an additional 180 calendar days, through Jan. 11, 2027, to regain compliance with the exchange’s minimum $1.00 closing bid price requirement.

To regain compliance, HKPD must maintain a closing bid price of at least $1.00 for a minimum of 10 consecutive business days before the extension expires.

The company said it intends to pursue all feasible measures to restore compliance but cautioned there is no assurance it will satisfy the listing requirement within the allotted period.

Nasdaq noted that Cellyan meets all other initial listing standards for the Nasdaq Capital Market except the minimum bid price requirement. The company also said it could pursue a reverse stock split, if necessary, to regain compliance.

The notification does not affect the current trading of HKPD shares, which will continue to trade on the Nasdaq Capital Market.

 **Read Also: Ross Gerber Slams 'Bubble Talk' as Earnings Season Begins: 'AI Is No Fad' and 'Valuations Are Quite Nice'** 

## Trading Metrics

Cellyan Biotechnology has a market capitalization of approximately $10.2 million, with a 52-week high of $2.58 and a 52-week low of $0.32.

Over the past 12 months, HKPD shares have fallen 69.03%.

**Benzinga Edge Stock Rankings** show negative price trends across the short-, medium-, and long-term time frames, reflecting continued weakness in the stock.

 **Read Also: Elon Musk Says It's 'True' to Prediction That Says Internet Browsers, Websites and Software Are Set to Disappear** 

*Image via Shutterstock/ Gorodenkoff*

### Related Stocks

- [HKPD.US](https://longbridge.com/en/quote/HKPD.US.md)
- [SSTK.US](https://longbridge.com/en/quote/SSTK.US.md)

## Related News & Research

- [Akanda wins Nasdaq extension to regain compliance with $2.5 million stockholders’ equity rule](https://longbridge.com/en/news/296145017.md)
- [T3 Defense regains Nasdaq $1.00 minimum bid compliance](https://longbridge.com/en/news/296134390.md)
- [Insider Selling: Synaptics (NASDAQ:SYNA) Insider Sells 6,056 Shares of Stock](https://longbridge.com/en/news/296409143.md)
- [Annita Tanini Sells 1,224 Shares of Keros Therapeutics (NASDAQ:KROS) Stock](https://longbridge.com/en/news/296537997.md)
- [Alphabet Inc. Makes New $9.82 Million Investment in Sana Biotechnology, Inc. $SANA](https://longbridge.com/en/news/296188088.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**